Wegovy doesn't work for me — what might be happening and what to do next

You're on month two and the scale hasn't moved much

Here is a scenario our prescribers encounter regularly. Someone starts Wegovy, feels hopeful for a few weeks, then reaches month two or three and feels let down. The numbers on the scale have barely changed. The frustration is real, but the timing matters enormously.

The first 12 to 16 weeks of semaglutide treatment are, for most people, a tolerability phase. You begin at 0.25mg, a dose chosen specifically to let your body adjust rather than to drive weight loss. The steps to 0.5mg, then 1mg, then 1.7mg, happen roughly every four weeks. You don't reach the 2.4mg maintenance dose until around week 17 at the earliest, and weight loss at sub-maintenance doses is typically modest.

So if Wegovy doesn't seem to be working at this stage, the most productive question is: which dose am I actually on? A quick check of your current prescription tells you this in under a minute. If you are not yet at 2.4mg, the medicine has not had its full opportunity to work. Understanding how Wegovy works in the body explains why the titration phase looks so different from the maintenance phase, and why patience at this point is grounded in evidence rather than wishful thinking. If you want a closer look at what the medicine is doing during any given seven-day period, our breakdown of how Wegovy works across a single week can help you see why progress during the early doses feels so different from progress at 2.4mg.

This does not mean dismissing your concerns. If side effects have made the titration unbearable, or if your prescriber has held you at a lower dose for another clinical reason, those conversations matter too.

You've been on the full dose for months and weight loss has stalled

A true plateau on 2.4mg, with no meaningful weight loss over six to eight weeks, is a different situation. The clinical factors behind inadequate response to Wegovy fall into a few broad categories.

Diet is the most common culprit, and it is not about willpower. Semaglutide slows gastric emptying and reduces appetite signals, but it does not override hunger entirely, and it does nothing about calorie density. People sometimes eat smaller portions of very energy-dense foods and see limited change as a result. Getting enough protein matters too; on a reduced appetite it is easy to undereat protein, which makes preserving muscle harder and slows the metabolic effects of weight loss.

Sleep and stress deserve equal attention. Chronic poor sleep raises cortisol and ghrelin; both drive appetite in ways that work against the medicine. Medicines that interact with semaglutide (including some antidepressants, antipsychotics and corticosteroids) can blunt the response. Your prescriber needs a full picture of everything you take.

If you are finding that the medicine is not delivering the results you expected, our guide on why Wegovy may not be working for you walks through the most common reasons and what can be done about each one. The NHS guidance on semaglutide for weight management notes that NICE recommends considering stopping if less than 5% weight loss has occurred after six months on the maintenance dose. That is a clinical review point, not an automatic stop, context determines the decision.

One honest note: a small proportion of people taking semaglutide have a genuinely limited response. The biology of why is still being studied. It is not a character flaw, and it does not mean every medicine will fail.

What your prescriber can actually do about it

If Wegovy doesn't work after a thorough review of dose, diet and lifestyle factors, there are real clinical options. The conversation with your prescriber might cover adjunct dietary support or a referral to a dietitian. It might cover whether a different GLP-1 or dual-agonist medicine suits you better.

Tirzepatide (Mounjaro) works on two gut-hormone receptors rather than one. In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine, tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks. That does not make it automatically right for you (eligibility, side-effect profile and clinical history all factor in) but it is a licensed UK option worth discussing.

There is also the question of the newer 7.2mg semaglutide dose, approved by the MHRA in January 2026 and now available in a single-dose pen. Early trial data suggested around 20.7% average weight loss at that dose, narrowing the gap with tirzepatide results. Whether that route is appropriate depends on individual clinical assessment.

For a sense of what options exist and how to talk through them, our treatment overview sets out the licensed medicines currently available. And if you want to explore whether a switch makes clinical sense for you, understanding personal response factors before you start is equally relevant for anyone reconsidering their current treatment.

The NHS patient page for semaglutide also covers when to seek medical advice and what questions to raise at your next review. It is worth reading before that appointment. Our prescribers at the nume clinical team are available seven days a week for aftercare questions, and every repeat prescription involves a fresh clinical review, so a plateau is exactly the kind of thing we expect to discuss, not overlook.

If you are thinking about switching or starting treatment elsewhere, you can start your free consultation with a GPhC-registered prescriber who will review your history before anything changes.